|
WO2020226889A1
|
|
Formulations of uridine triacetate in triacetin
|
|
AU2019215105A1
|
|
Compositions and devices for systemic delivery of uridine
|
|
EP3182980A1
|
|
Treatment of glycosylation deficiency diseases
|
|
WO2014120995A2
|
|
Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
|
|
US2016016997A1
|
|
Stem cell mobilization and tissue repair and regeneration
|
|
AU2013200226A1
|
|
Compounds and method for reducing uric acid
|
|
US2014088006A1
|
|
Stem Cell Mobilization and Tissue Repair and Regeneration
|
|
WO2012125533A1
|
|
3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
|
|
WO2012033720A1
|
|
Benzoic acid compounds for reducing uric acid
|
|
CN102573462A
|
|
3-substituted compounds for reducing uric acid
|
|
WO2010132434A1
|
|
Determining the severity of 5-fluorouracil overdose
|
|
EP2365746A1
|
|
Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
|
|
EP2285777A1
|
|
Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid
|
|
AU2009243028A1
|
|
Tetrazole compounds for reducing uric acid
|
|
UA104289C2
|
|
Derivatives of tetrazole for decline of level of urinary acid
|
|
AU2009258040A1
|
|
Compounds and method for reducing uric acid
|
|
EP2240024A1
|
|
Compounds for the treatment of metabolic disorders
|
|
KR20090038908A
|
|
Combination treatment of metabolic disorders
|
|
US2010234464A1
|
|
Compounds for the treatment of metabolic disorders
|
|
US2009163576A1
|
|
Compounds for the treatment of metabolic disorders
|
